Diabetic Retinopathy Screening Guidelines

Initial Screening Recommendations

The American Diabetes Association recommends that patients with type 2 diabetes have an initial dilated and comprehensive eye examination by an ophthalmologist or optometrist at the time of diabetes diagnosis, while patients with type 1 diabetes should have this examination within 5 years after the onset of diabetes 1, 2, 3
Patients with gestational diabetes do not require eye examinations during pregnancy as they are not at increased risk of developing diabetic retinopathy 1

For patients with no retinopathy and well-controlled glycemia, screening every 1-2 years may be considered 1, 2, 4
Patients with any level of diabetic retinopathy should have subsequent dilated retinal examinations at least annually 1, 2
Those with progressing or sight-threatening retinopathy require more frequent examinations 1, 4

Pregnant women with pre-existing diabetes should have an eye examination before pregnancy or in the first trimester, then monitoring every trimester and for 1 year postpartum 1, 4
Rapid implementation of intensive glycemic management may be associated with early worsening of retinopathy, requiring closer monitoring 1
Children and adolescents with diabetes need regular screening as they are also at risk for complications 2

Any level of macular edema requires prompt referral to an ophthalmologist 4, 5
Severe nonproliferative diabetic retinopathy and any proliferative diabetic retinopathy also necessitate prompt referral to an ophthalmologist 4, 5

Longer duration of diabetes increases the risk of retinopathy 5, 6
Chronic hyperglycemia accelerates progression of retinopathy 5, 6
Hypertension, diabetic kidney disease, and dyslipidemia are associated with an increased risk of retinopathy development and progression 5, 6

The traditional approach involves a dilated eye examination by an ophthalmologist or optometrist 1, 2
Alternative approaches include retinal photography with remote reading or the use of validated assessment tools, which can improve access to screening 1, 2, 7
Newer technologies, such as artificial intelligence systems authorized by the FDA, can detect more than mild diabetic retinopathy and diabetic macular edema 7

Asymptomatic disease can occur, emphasizing the importance of regular screening for patients with proliferative diabetic retinopathy or macular edema 2, 5
The presence of retinopathy is not a contraindication to aspirin therapy for cardioprotection, as it does not increase the risk of retinal hemorrhage 4, 5

Prompt diagnosis allows timely intervention that may prevent vision loss in asymptomatic individuals with advanced diabetic eye disease 1, 2
Treatment efficacy, such as panretinal photocoagulation, reduces the risk of severe vision loss from proliferative diabetic retinopathy 5